Omalizumab in Children with Severe Allergic Asthma: The Italian Real-Life Experience

BACKGROUND: Anti-IgE treatment represents a major breakthrough in the therapeutic management of severe allergic asthma. To date, omalizumab is the only biological drug currently licensed as add-on therapy in children aged > 6 years with moderate-to-severe and severe allergic asthma uncontrolled a...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Curr Respir Med Rev
Main Authors: Licari, Amelia, Castagnoli, Riccardo, Denicolò, Chiara, Rossini, Linda, Seminara, Manuela, Sacchi, Lucia, Testa, Giorgia, De Amici, Mara, Marseglia, Gian Luigi
Format: Artigo
Sprog:Inglês
Udgivet: Bentham Science Publishers 2017
Fag:
Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5684803/
https://ncbi.nlm.nih.gov/pubmed/29213221
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2174/1573398X13666170426094536
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker